Isthmus Partners LLC Purchases 450 Shares of Haemonetics Co. (NYSE:HAE)

Isthmus Partners LLC lifted its position in Haemonetics Co. (NYSE:HAE) by 1.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 40,220 shares of the medical instruments supplier’s stock after purchasing an additional 450 shares during the quarter. Isthmus Partners LLC’s holdings in Haemonetics were worth $3,140,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Parkside Financial Bank & Trust grew its position in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 240 shares during the last quarter. AlphaQuest LLC increased its position in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after buying an additional 1,826 shares during the period. KBC Group NV lifted its holdings in Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 712 shares during the period. iSAM Funds UK Ltd bought a new stake in Haemonetics during the 3rd quarter valued at approximately $204,000. Finally, Ashton Thomas Private Wealth LLC purchased a new position in shares of Haemonetics during the 4th quarter worth approximately $284,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Up 2.2 %

HAE opened at $68.70 on Monday. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97. The firm’s 50 day simple moving average is $69.77 and its two-hundred day simple moving average is $75.74. The company has a market capitalization of $3.45 billion, a PE ratio of 27.05, a PEG ratio of 1.11 and a beta of 0.43. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Needham & Company LLC lowered their target price on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. Raymond James reissued a “strong-buy” rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.